Clinical trial · Observational
Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study
NCT02298998CI-TRIAL-00052244completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a two-arm, randomized-controlled pilot study with 2 year duration. The "intervention" refers to surveillance based on the European Association of Urology (EAU) guidelines and the "control" refers to surveillance based on the American Urological Association (AUA) guidelines.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control | Other | — | UNRESOLVED |
| Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Intervention
- description
- The intervention group refers to surveillance based on the EAU guidelines.
- interventionNames
- Other: Intervention
- label
- Control
- description
- The control group refers to surveillance based on the AUA guidelines.
- interventionNames
- Other: Control
Primary outcomes (2)
- measure
- Demonstrate feasibility of study recruitment and retention in order to help plan for subsequent phase III study.
- timeFrame
- 2 years
- measure
- Develop methods for assessing patient satisfaction and costs associated with cystoscopy during bladder cancer surveillance.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must have non-muscle invasive low-grade, papillary (Ta) bladder cancer. * Must have a negative cystoscopy following most recent biopsy. * Must be able to give informed consent. * Must be age 18 or older. * Must be at low- or low-intermediate risk for disease recurrence and progression according to the EAU guidelines. Exclusion Criteria: * Have a history of invasive (\>=T1) bladder cancer. * Have a history of carcinoma-in-situ (CIS). * Unable to give informed consent. * \< 18 or younger. * Variant histology (micropapillary, nested variant, non-urothelial cell carcinoma elements). * Had a surveillance cystoscopy following most recent biopsy.
References
Publications (1)
- DERIVEDChung D, Kassouf W, Agnihotram R, Alday H, Tajzler C, Eskandari A, Breau R, Kulkarni G, Chung P, Fairey A, Lodde M, Hyndman E, Alimohamed N, Rendon R, Black P, Nayak JG. Outcomes Among Rural and Urban Patients With High-Risk Nonmuscle-Invasive Bladder Cancer: Results From the Canadian Bladder Cancer Information System. J Urol. 2026 Mar;215(3):286-293. doi: 10.1097/JU.0000000000004836. Epub 2025 Oct 30. PMID 41166647